Anti-relapse therapy of endometriosis: possible variations

Н. Ф. Захаренко, S.I. Regeda, I.P. Manoliak, V.S. Solskyy
In: REPRODUCTIVE ENDOCRINOLOGY · 2021 · pp. 38–42 · doi:10.18370/2309-4117.2021.57.38-42 · W3164580931
article OA: diamond CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Bioavailable curcumin Longimin® in combination with dienogest demonstrated greater clinical efficacy and safety in preventing endometriosis relapse compared to dienogest alone, reducing recurrence and pain while improving emotional state.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

The paper studied 45 women (mean age 29.3 years) with extragenital endometriosis after surgery to assess whether bioavailable curcumin (Longimin®) could enhance anti-relapse therapy beyond hormonal suppression. All participants received dienogest 2 mg/day for 6 months, after which 22 women received no further drug while 23 received 400 mg bioavailable curcumin for another 6 months, followed by 12 months of observation. Newly formed endometriosis foci occurred in 13.6% of the non-curcumin group, while no recurrence was observed in the sequential dienogest plus curcumin group; additionally, chronic pelvic pain and anxiety increased after dienogest alone, whereas intermenstrual pain decreased and anxiety scores improved during and after curcumin add-on. This study does not report randomization/blinding and the small group sizes limit certainty. This paper is centrally about endometriosis — it evaluates sequential dienogest plus bioavailable curcumin as anti-relapse therapy after surgical treatment of extragenital endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Research aim: to determine the clinical efficacy and safety of bioavailable curcumin Longimin® in the complex anti-relapse therapy of patients with extragenital endometriosis after surgery.Materials and methods. Study involved 45 women with a mean age of 29.3 ± 3.6 years with a diagnosis of extragenital endometriosis. After surgical treatment of this disease all patients were prescribed dienogest 2 mg/day for 6 months with anti-relapse purpose. After that, 22 patients did not receive drug treatment (group 1) and other 23 women started a six-month course of 400 mg bioavailable curcumin (group 2).Results. After 12 months of observation 3 cases (13.6%) of newly formed foci of endometriosis were found among patients of group 1, two of which were multi-endometriomas, and the third was retrocervical heterotopia. There were no signs of recurrence in the group of sequential use of dienogest and bioavailable curcumin. In addition, 6 months after completion of hormonal treatment the number of women with chronic pelvic pain in group 1 was increased and average score on a visual analogue scale (VAS) was increased by 80% (p ≤0.05). It was accompanied by a stable moderately high level of anxiety throughout the observation period. At the same time the number of women who complained of intermenstrual pain in group 2 decreased from 15 to 13, and the average VAS score decreased by 13% (p ≥0.05) during the treatment period. Patients in group 2 noted an improvement in emotional control during treatment, which resulted in the average score decrease on the scale of personal and situational anxiety of the Spielberg-Hanin's questionnaire (25% and 30% respectively, p ≤0.05).Conclusions. The nature of the endometriosis development and progression is multipathogenetic. Blocking only its hormonal link, especially in cases of extragenital forms, may not be sufficient to stop the pathological process and prevent recurrence in the long term. Оbtained results of sequential course of dienogest and bioavailable curcumin Longimin® with anti-relapse purpose showed the wider clinical effectiveness of this therapy, which is probably based on additional inhibition of systemic inflammation, proliferation, stroma and psychogenic component of disease.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

endometriosischronic_pelvic_pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK